

NOV. 27. 2006 4:19PM

RECEIVED  
CENTRAL FAX CENTER

NO. 9643 P. 5

NOV 27 2006

Page 2 of 20  
USSN 10/810,999  
6696.US.D1  
Response to Office Action

REMARKS

Claims 1-26 and 41-79 are pending in the application. Claims 3-15 and 41-70 have been withdrawn from consideration. Accordingly, Claims 1, 2, 16-26, and 71-79 are presently under consideration by the Examiner. Claims 1, 2, 16-26, and 71-79 stand rejected pursuant to 35 U.S.C. § 112, first paragraph. Claims 71-73 also stand rejected pursuant to 35 U.S.C. § 112, second paragraph. Applicants respectfully traverse the rejections.

Claims 1 and 16 have been amended to delete the term "prodrug". As such, the rejection of Claims 1 and 16, and dependent Claims 2, 28-40, and 71-79, has been rendered moot in light of the amendments. Claim 1 also has been amended to delete any non-elected subject matter of Claims 3-15 and 41-70.

Regarding Claims 76-79, the Examiner contends that the specification fails to describe the definition of possible additional active ingredients. Applicants respectfully submit that the guidance provided on page 5, line 8, through page 6, line 12, describes that the compound of the invention can be favorably provided with another analgesic compound to provide pain relief and treatment of disorders ameliorated by controlling neurotransmitter release. The specification details characteristics of classes of suitable compounds, e.g. non-steroid anti-inflammatory agents, opioids, tricyclic antidepressants, and anticonvulsants, as well as providing specific, individual examples of suitable additional active ingredients. Accordingly, Applicants respectfully request the rejection be withdrawn.

The Examiner finds that Claims 71-73 are vague and indefinite in view of the guidance provided regarding the diseases capable of being ameliorated by the administration of the claimed compounds. Applicants respectfully traverse the rejection.

Claim 71 relates to a composition comprising a compound of formula I in a pharmaceutically acceptable carrier. There are no claim elements directed to a disease state. Applicants respectfully submit that amended Claim 71 is patentable in accordance with 35 U.S.C. § 112, second paragraph and request the rejection be withdrawn.

Page 3 of 20  
USSN 10/810,999  
6696.US.D1  
Response to Office Action

Claims 72 has been canceled. Claim 73 has been amended to include specific disorders to further clarify the claimed methods. As amended, Claim 73 relates to a method of treating a disorder in a mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of Claim 1 wherein the disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, memory dysfunction, Tourette's syndrome, sleep disorders, attention deficit hyperactivity disorder, neurodegeneration, inflammation, neuroprotection, amyotrophic lateral sclerosis, anxiety depression, mania, schizophrenia, eating disorders, AIDS-induced dementia, epilepsy, urinary incontinence, Crohn's disease, migraines, pain, PMS, erectile dysfunction, substance abuse, smoking cessation, and inflammatory bowel syndrome. Applicants respectfully submit that the administration of the claimed compounds can provide treatment for the named conditions as is supported in the specification, as originally filed, at least on pages 48, line 28, through page 49, line 22.

Applicants further add new Claim 80 to include the compound (3aR,6aR)-1-(3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole and add new Claims 81 and 82 relating to a pharmaceutical composition containing and a method of using the same. Applicants respectfully submit that such amendment of the claims adds no new matter in that the claimed subject matter related to (3aR,6aR)-1-(3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole is described in the specification, as filed, on at least pages 155, line 19, through, page 156, line 15, as well as the claims and Schemes.

For the convenience of the Examiner, a complete set of the claims is provided herewith in accordance with the guidelines for the revised format of amendments in view of 37 C.F.R. § 1.121. Applicants reserve the right to file divisional applications on any non-pending or non-elected subject matter.

Should the Examiner have questions or concerns regarding the foregoing, she is respectfully invited to contact the undersigned by telephone at the phone number provided below.


NOV. 27. 2006 4:20PM

NO. 9643 P. 7

Page 4 of 20  
USSN 10/810,999  
6696.US.D1  
Response to Office Action

ABBOTT LABORATORIES  
Customer No. 23492  
Telephone: (847) 937-8272  
Facsimile: (847) 938-2623

Respectfully submitted,  
*Schrimpf, et al.*

  
Portia Chen  
Registration No. 44,075  
Attorney for Applicants